Inhalable aerosol, raw material composition thereof and preparation methods thereof

A raw material composition, aerosol technology, applied in aerosol delivery, drug combination, pharmaceutical formulation and other directions, can solve the problems of uneven particle distribution, loss of preparation method, etc., and achieve the effect of reducing pollution and low loss

Active Publication Date: 2017-10-13
SHANGHAI SINE PHARMA LAB
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The technical problem to be solved by the present invention is to overcome defects such as inhomogeneous distribution of particles in the inhalation aerosol in the inhalation aerosol of mometasone furoate fumarate and formoterol in the prior art, serious loss in the preparation method, and provide A kind of inhalation aerosol, its raw material composition and preparation method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhalable aerosol, raw material composition thereof and preparation methods thereof
  • Inhalable aerosol, raw material composition thereof and preparation methods thereof
  • Inhalable aerosol, raw material composition thereof and preparation methods thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Produced on a scale of 10,000 bottles

[0058] (1) Preparation of mometasone furoate pharmaceutical granules

[0059] Add 240 grams of mometasone furoate into a solvent (such as ethanol and / or dichloromethane) to dissolve, the amount of solvent is not specifically limited, as long as a uniform solution can be obtained; then add it to the extraction kettle; or directly add the bran Add mometasone furoate into the extraction kettle; fill a certain amount of carbon dioxide in the extraction kettle, control the temperature of the extraction kettle to be 150°C, and control the pressure of the extraction kettle to be 500bar; mometasone furoate reaches a saturated state in the supercritical fluid, and Stable for 15 minutes, mometasone furoate is ejected through a nozzle to form spherical particles, and the particle diameter (d90) of the particles is less than 5 microns (for example, less than 2 microns) (the loss of the drug particles is generally less than 5% by this method, ...

Embodiment 2

[0066] All the other are with embodiment 1, and wherein, the operation of step (2) is as follows:

[0067] Dissolve 6 grams of formoterol fumarate in a solvent (such as methanol), use spray drying equipment, spray speed 2ml / min; spray dry at a temperature of 90°C, collect formoterol fumarate drug particles, particles The particle size d50 = 4 microns.

Embodiment 3

[0069] All the other are with embodiment 1, and wherein, the operation of step (2) is as follows:

[0070] Dissolve 6 grams of formoterol fumarate in a solvent (such as methanol), use spray drying equipment, and spray speed 4ml / min; spray dry at a temperature of 120 ° C, and collect formoterol fumarate drug particles, particles The particle size d50 = 4 microns.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses an inhalable aerosol, a raw material composition thereof and preparation methods thereof. The raw material composition of the inhalable aerosol, disclosed by the invention, contains a medicinal active component and a propellant, wherein the medicinal active component contains a long-acting beta-receptor agonist and glucocorticoid; the propellant comprises tetrafluoroethane. The inhalable aerosol disclosed by the invention contains the raw material composition, a pressure container and a valve system. The inhalable aerosol uses the tetrafluoroethane as the propellant; during preparation, medicine particles are prepared by a supercritical method and a spray drying method, so that the inhalable aerosol with uniform particle distribution can be obtained; in the preparation method, the loss is low; in addition, the single dose of the inhalable aerosol is adjusted, so that the greenhouse gas amount of a product is effectively reduced.

Description

technical field [0001] The invention relates to an inhalation aerosol, its raw material composition and a preparation method. Background technique [0002] Mometasone furoate formoterol fumarate inhalation aerosol is a compound drug of glucocorticoid and long-acting β receptor agonist, and its product DULERA containing HFC227 was developed by Merck. The drug is indicated for the treatment of asthma in patients ≥ 12 years of age not adequately controlled by moderate to high doses of inhaled corticosteroids, and is not intended for the treatment of patients with acute asthma. The drug is equipped with an electronic counting device, which is counted by the push sensor of the valve. ) Two dosage specifications. [0003] The results of the clinical study confirmed that compared with mometasone furoate and placebo alone, the lung function of patients treated with mometasone furoate formoterol fumarate inhalation aerosol (measured at 0-12h corresponding to Mean area under the co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/58A61K31/167A61K9/72A61P11/06
CPCA61K9/008A61K9/124A61K31/167A61K31/58A61K45/06A61K2300/00
Inventor 邵奇荆志欣周雅茹洪晨文彬孙宁云
Owner SHANGHAI SINE PHARMA LAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap